Genitourinary Cancers

Enfortumab vedotin plus pembrolizumab enhanced survival rates for patients with muscle-invasive bladder cancer not eligible for cisplatin chemotherapy.

Fruquintinib plus sintilimab significantly enhanced PFS in advanced RCC offering a promising second-line treatment option.

Lenvatinib and everolimus significantly enhanced progression-free survival in metastatic clear cell RCC compared with cabozantinib, despite higher toxicity rates.

Updated results from SunRISe-4 support further investigation of the gemcitabine intravesical system plus cetrelimab in MIBC.

Data from POTOMAC support durvalumab plus BCG and induction and maintenance therapy as a new treatment option in BCG-naive, high-risk NMIBC.

New findings reveal that adding durvalumab to neoadjuvant chemotherapy does not enhance HRQOL in muscle-invasive bladder cancer patients.

Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.

Updated results from CheckMate 274 support adjuvant nivolumab as a standard of care for patients with high-risk muscle-invasive urothelial carcinoma.

The safety profile of the atezolizumab with Bacillus Calmette-Guérin in NMIBC was consistent with that of each individual agent.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Anticipated data from the ESMO Congress 2025 may have implications for standards of care across prostate and bladder cancer groups.

Data from the FRUSICA-2 trial may support fruquintinib/sintilimab as a “valuable” option for patients with advanced renal cell carcinoma.

Data support the intravesical mitomycin solution’s role as an innovative option for those with recurrent, low-grade, intermediate-risk NMIBC.

Casdatifan, administered at 100 mg once daily, achieved a confirmed ORR of 35% in patients with pretreated metastatic kidney cancer.

No toxicity-related discontinuations were seen with adjuvant radiotherapy among patients with muscle-invasive bladder cancer.

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Gary Steinberg, MD, discusses the role of patient counseling and surveillance when using the gemcitabine intravesical system for BCG-unresponsive NMIBC.

Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Gary Steinberg, MD, compared the AE profile of the gemcitabine intravesical system for BCG-unresponsive NMIBC with other intravesical therapies.

Gary Steinberg, MD, discusses the clinical significance of the new FDA-approved gemcitabine intravesical system for BCG-unresponsive NMIBC.

Panelists and presenters attending World GU 2025 shared their perspectives on optimizing the management of prostate, kidney, and bladder cancers.

Gary Steinberg, MD, highlights the FDA approval of the gemcitabine intravesical system and what this means for patients with BCG-unresponsive NMIBC.

Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.

Machine learning–based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.